Kallyope snags $21 mln
New York City-based Kallyope Inc., a biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, has secured $21 million in funding. The lead investor was Bill Gates. Other investors included Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital and Two Sigma Ventures.
5 December 2018•1 min read
